Navidea Biopharmaceuticals Retains Stern IR for Investor Relations Services
Navidea Biopharmaceuticals Retains Stern IR for Investor Relations Services
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has retained Stern Investor Relations, Inc. to provide strategic advisory services and execute and enhance the Company's investor relations program. Stern IR is a full service investor relations firm specializing in entrepreneurial healthcare and biotechnology companies.
The firm will provide strategic counsel and execution to advance Navidea's leadership in innovative, precision diagnostics that improve diagnostic accuracy, clinical decision-making and patient care. Stern's focus will be to improve and broaden the Company's exposure within the investment community and support its efforts to establish additional partnerships and relationships in the healthcare and financial communities.
"As we move forward in advancing the field of precision diagnostics through the commercialization of the recently approved Lymphoseek® and the continued progression and expansion of our promising pipeline of radiopharmaceuticals in oncology and neurology, we are very pleased to be working with an experienced, well-regarded firm like Stern IR at this pivotal period of growth for Navidea," said Mark Pykett, President and CEO of Navidea.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms - Lymphoseek®, NAV4694, NAV5001 and RIGScanTM - to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
About Stern Investor Relations
Stern Investor Relations, Inc. (Stern IR) is a leading investor relations firm specializing in investor relations consulting services to healthcare and biotechnology companies in the U.S. and around the world. Since its inception in 1998, Stern IR has worked with more than 200 biotechnology, specialty pharmaceuticals, devices, healthcare services and industrial biotechnology companies in all stages of development, including bellwethers in the industry, small‐ and mid‐cap companies, recent IPOs and private companies. Stern IR is based in New York City. For more information, please visit www.sternir.com.
Navidea Biopharmaceuticals
Brent Larson
Senior Vice President & CFO
614-822-2330
blarson@navidea.com
or
Investor Relations:
Stern Investor Relations, Inc.
Beth DelGiacco
212-362-1200
beth@sternir.com
KEYWORDS: United States North America Ohio
INDUSTRY KEYWORDS:
The article Navidea Biopharmaceuticals Retains Stern IR for Investor Relations Services originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
